Cystic Fibrosis

Drug delivery company signs licensing agreement for Cystic Fibrosis treatment

Published in Gene Therapy Weekly, October 28th, 2004

Oriel Therapeutics announced that it has signed a development and licensing agreement with an undisclosed U.S.-based biotechnology company to develop a novel therapy for the treatment of cystic fibrosis.

This therapy will be based on Oriel Therapeutics' proprietary dry powder inhalation technology incorporating the partner's proprietary compounds that represent a novel mode of action to improve airway function.

Cystic fibrosis is a genetic disorder that affects approximately 30,000 children and adults in the United States. The disease causes the body to produce abnormally thick, sticky mucus that clogs the lungs and leads to life-threatening...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-10-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry